 |
| |
| Feb-06-20 | Initiated |
Mizuho |
Buy |
|
|
| Jan-07-20 | Initiated |
RBC Capital Mkts |
Sector Perform |
$86 |
|
| Dec-26-19 | Reiterated |
Cowen |
Outperform |
$90 → $98 |
|
| Sep-26-19 | Upgrade |
Citigroup |
Neutral → Buy |
$87 → $90 |
|
| Aug-20-19 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
$80 |
|
| Jun-27-19 | Upgrade |
Wolfe Research |
Underperform → Peer Perform |
|
|
| Jun-26-19 | Upgrade |
SVB Leerink |
Mkt Perform → Outperform |
$88 |
|
| May-28-19 | Initiated |
Goldman |
Neutral |
|
|
| Apr-29-19 | Upgrade |
BMO Capital Markets |
Underperform → Market Perform |
|
|
| Mar-25-19 | Downgrade |
Argus |
Buy → Hold |
|
|
| Jan-23-19 | Initiated |
UBS |
Neutral |
$91 |
|
| Jan-03-19 | Downgrade |
BofA/Merrill |
Buy → Neutral |
|
|
| Dec-26-18 | Initiated |
Standpoint Research |
Buy |
|
|
| Oct-22-18 | Reiterated |
SunTrust |
Buy |
$157 → $135 |
|
| Oct-04-18 | Reiterated |
BofA/Merrill |
Buy |
$107 → $106 |
|
| Jun-01-18 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
|
|
| May-30-18 | Downgrade |
Credit Suisse |
Neutral → Underperform |
|
|
| Jan-30-18 | Reiterated |
Morgan Stanley |
Equal-Weight |
$99 → $131 |
|
| Jan-29-18 | Downgrade |
Leerink Partners |
Outperform → Mkt Perform |
|
|
| Oct-30-17 | Reiterated |
Leerink Partners |
Outperform |
$108 → $107 |
|
|
|
| Feb-25-20 07:29AM | Form 8.3 - Abbvie Plc- Amendment Business Wire |
| 06:24AM | Form 8.3 - ABBVIE INC Business Wire |
| 06:20AM | AbbVie Stock Falls 3% Investing.com |
| 05:22AM | FORM 8.3 - ABBVIE INC - Amendment Business Wire |
| 04:49AM | Form 8.3 - Abbvie Plc - Amendment Business Wire |
| Feb-24-20 09:00AM | Should You Bet On AbbVie Stock As Its $63 Billion Acquisition Looms? Investor's Business Daily |
| 09:00AM | AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes PR Newswire |
| 07:52AM | FORM 8.3 - ABBVIE INC Business Wire |
| Feb-21-20 09:58AM | Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS Zacks |
| 05:35AM | Form 8.3 - Abbvie Plc Business Wire |
| Feb-20-20 04:46PM | Disagreement on Japan Evacuees; Cops Quarantined: Virus Update Bloomberg |
| 01:14PM | AbbVie Declares Quarterly Dividend PR Newswire |
| 12:37PM | David Abrams Buys 2 Stocks in 4th Quarter GuruFocus.com |
| 11:42AM | Nations largest insurer invests in Waltham healthcare AI startup American City Business Journals |
| 09:53AM | FORM 8.3 - ABBVIE INC - Amendment Business Wire |
| 06:06AM | Form 8.3 - Abbvie Plc Business Wire |
| Feb-19-20 02:02PM | Abbott Laboratories: Why Adding More of This Health Care Giant Makes Sense GuruFocus.com |
| 09:51AM | Jim Simons: The Investing Guru Bets on These 3 Healthcare Stocks TipRanks |
| 09:18AM | Form 8.3 - ABBVIE INC - AMENDMENT Business Wire |
| 08:00AM | AbbVie to Present at the Cowen 40th Annual Health Care Conference PR Newswire |
| 07:11AM | FORM 8.3 - ABBVIE INC Business Wire |
| Feb-18-20 02:56PM | Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan Reuters |
| Feb-17-20 08:36AM | FORM 8.3 - ABBVIE INC - Amendment Business Wire |
| 07:00AM | FORM 8.3 - ABBVIE INC Business Wire |
| 05:04AM | Form 8.3 - ABBVIE INC - AMENDMENT Business Wire |
| Feb-15-20 01:17PM | Veteran strategist eyes health care and financials in anticipation of choppy and frustrating markets MarketWatch |
| Feb-14-20 09:52AM | Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails Zacks |
| 09:22AM | The Keys to Successfully Timing the Markets - February 14, 2020 Zacks |
| 06:18AM | FORM 8.3 - ABBVIE INC Business Wire |
| Feb-13-20 07:10AM | FORM 8.3 - ABBVIE INC Business Wire |
| 06:00AM | AbbVie's SKYRIZI Now Listed on the Nova Scotia Formulary for the Treatment of Moderate to Severe Plaque Psoriasis CNW Group |
| Feb-12-20 04:27PM | Edited Transcript of ABBV earnings conference call or presentation 7-Feb-20 2:00pm GMT Thomson Reuters StreetEvents |
| 10:30AM | Buy AbbVie for its Growth Prospects, Yield and Low Valuation GuruFocus.com |
| 09:59AM | Form 8.3 - Abbvie Plc - Amendment Business Wire |
| 09:43AM | The Zacks Analyst Blog Highlights: AbbVie, Accenture, TOTAL, Amazon.com and Intuit Zacks |
| 07:23AM | FORM 8.3 - ABBVIE PLC Business Wire |
| 05:16AM | Form 8.3 - ABBVIE INC - Amendment Business Wire |
| Feb-11-20 02:18PM | Coronavirus update: 1,018 deaths, a new case in San Diego, 195 evacuees expected to leave quarantine MarketWatch |
| 01:09PM | Top Stock Research Reports for AbbVie, Accenture, TOTAL & Others Zacks |
| 08:00AM | AbbVie to Present at the SVB Leerink 9th Annual Global Healthcare Conference PR Newswire |
| 07:33AM | Form 8.3 - ABBVIE INC Business Wire |
| 04:51AM | Form 8.3 - Abbvie Plc - Amendment Business Wire |
| Feb-10-20 04:18PM | Allergan Rides Botox Sales To Top Forecasts As AbbVie Merger Looms Investor's Business Daily |
| 03:11PM | Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates Zacks |
| 11:47AM | Wall Street Opens Higher Monday GuruFocus.com |
| 09:31AM | Allergan Tops Q4 Earnings Forecast, Sees $63 Billion AbbVie Deal Closing in Q1 TheStreet.com |
| 09:03AM | Easy Investing Secrets to an Early Retirement - February 10, 2020 Zacks |
| 07:14AM | Allergan's stock rises as adjusted profit, revenue beat expectations MarketWatch |
| 06:53AM | Form 8.3 - ABBVIE INC Business Wire |
| 04:48AM | AbbVie Stock Rises 3% Investing.com |
| Feb-07-20 04:22PM | Stocks end lower as market retreats from records MarketWatch +5.86% |
| 04:08PM | AbbVie Stock Breaks Out As Humira Sales Top Bearish Expectations Investor's Business Daily |
| 04:01PM | US Stock Market Red on Friday GuruFocus.com |
| 02:07PM | AbbVie's (ABBV) Q4 Earnings Beat, 2020 View Solid, Stock Up Zacks |
| 10:34AM | FORM 8.3 - ABBVIE PLC - AMENDMENT Business Wire |
| 10:24AM | Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split Zacks |
| 10:20AM | AbbVie Tops Q4 Profit Forecast, Sees Solid 2020 as New Drugs Boost Sales TheStreet.com |
| 09:33AM | AbbVie Jumps on Strong Earnings. Thats Not the Only Reason. Barrons.com |
| 09:05AM | AbbVie (ABBV) Q4 Earnings and Revenues Beat Estimates Zacks |
| 08:11AM | AbbVie Reports Q4 Earnings Beat Benzinga |
| 08:10AM | AbbVie's stock rises on strong earnings MarketWatch |
| 07:46AM | New drugs contribute to AbbVie's upbeat 2020 view; shares hit year-high Reuters |
| 07:43AM | AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results PR Newswire |
| 05:45AM | Form 8.3 - ABBVIE INC Business Wire |
| 04:33AM | AbbVie Stock Rises 3% Investing.com |
| 02:45AM | AbbVie Earnings Beat, Revenue Inline In Q4 Investing.com |
| Feb-06-20 08:39PM | AbbVie boosts 2020 outlook despite competition from generic drugs Financial Times |
| 01:21PM | Q4 Earnings Outlook For AbbVie Benzinga |
| 11:38AM | Form 8.3 - ABBVIE INC - Amendment Business Wire |
| 10:54AM | AbbVie Climbs Pre-Earnings on Analyst Nod, Coronavirus Drug Demand TheStreet.com |
| 10:51AM | Allergan (AGN) to Report Q4 Earnings: What's in the Cards? Zacks |
| 03:43AM | Form 8.3 - ABBVIE INC - AMENDMENT Business Wire |
| Feb-05-20 11:17AM | Regeneron Expands Agreement to Develop Coronavirus Therapy Zacks |
| 10:37AM | Can Humira/Cancer Drugs Help AbbVie (ABBV) Beat Q4 Earnings? Zacks |
| 09:28AM | FORM 8.3 - ABBVIE INC - Amendment Business Wire |
| 08:45AM | RINVOQ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis PR Newswire |
| 08:43AM | AbbVie Stock Rises 3% Investing.com |
| 06:55AM | Form 8.3 - ABBVIE INC Business Wire |
| 04:48AM | FORM 8.3 - ABBVIE INC AMENDMENT Business Wire |
| Feb-04-20 04:15PM | Merck's Keytruda: How Long Can It Fend Off Cancer-Treatment Rivals? Investor's Business Daily |
| 12:08PM | Merck's Keytruda: How Long Can It Fend Off Cancer-Treatment Rivals? Investor's Business Daily |
| 09:44AM | FORM 8.3 - ABBVIE PLC - AMENDMENT Business Wire |
| 08:03AM | AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards? Zacks |
| 07:17AM | FORM 8.3 - ABBVIE INC Business Wire |
| Feb-03-20 05:45PM | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know Zacks |
| 04:26PM | CDC Readies for Pandemic; Long Vaccine Timeline: Virus Update Bloomberg |
| 11:16AM | Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up Zacks |
| 10:10AM | VVUS: ZenPep Deal Demonstrates PERT Interest Zacks Small Cap Research |
| 10:10AM | AZRX: EPI Treatment in the News Zacks Small Cap Research |
| 06:20AM | AZRX: EPI Treatment in the News Zacks Small Cap Research |
| 03:25AM | Stocks - Apple Falls in Premarket; Drug Reports Lift Gilead, AbbVie Investing.com |
| Jan-31-20 10:16PM | Top Marijuana Stocks That Pay Dividends Investopedia |
| 04:53PM | Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study Zacks |
| 09:54AM | Form 8.3 - Abbvie Plc Business Wire |
| 08:54AM | Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat Zacks |
| 08:25AM | Decisions, Decisions: AbbVie or Bristol-Myers Squibb? TheStreet.com |
| 07:15AM | AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis PR Newswire |
| 06:55AM | AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia PR Newswire |
| Jan-30-20 06:21PM | J&J (JNJ) Plans to Develop Vaccine for New Coronavirus Zacks |
| 03:40PM | Coronavirus update: US records first human-to-human transmission as WHO declares global emergency Yahoo Finance |
|
|
|
|
| AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| RICHMOND TIMOTHY J. | EVP, Chief HR Officer | Sep 27 | Sale | 75.02 | 15,515 | 1,163,873 | 0 | Oct 01 05:52 PM | | Schumacher Laura J | Vice Chairman | Sep 16 | Buy | 70.42 | 25,000 | 1,760,523 | 164,838 | Sep 18 04:25 PM | | Donoghoe Nicholas | SVP, Enterprise Innovation | Aug 29 | Buy | 66.19 | 7,525 | 498,057 | 13,090 | Aug 30 04:08 PM | | Stewart Jeffrey Ryan | SVP, US Commercial Operations | Aug 16 | Buy | 64.44 | 15,552 | 1,002,169 | 65,304 | Aug 20 04:16 PM | | AUSTIN ROXANNE S | Director | Aug 01 | Buy | 65.66 | 25,000 | 1,641,400 | 117,114 | Aug 02 05:02 PM | | AUSTIN ROXANNE S | Director | Jul 31 | Buy | 66.02 | 30,000 | 1,980,690 | 92,114 | Aug 02 05:02 PM | | AUSTIN ROXANNE S | Director | Jul 30 | Buy | 66.35 | 10,000 | 663,500 | 62,114 | Jul 31 04:46 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | Jul 29 | Buy | 67.28 | 30,000 | 2,018,385 | 75,763 | Jul 31 04:46 PM | | AUSTIN ROXANNE S | Director | Jun 26 | Buy | 67.50 | 11,500 | 776,250 | 52,114 | Jun 28 04:47 PM | | CHASE WILLIAM J | EVP, Finance & Administration | Jun 26 | Buy | 67.30 | 30,400 | 2,045,920 | 169,552 | Jun 28 04:47 PM | | RAPP EDWARD J | Director | Jun 26 | Buy | 67.30 | 7,500 | 504,750 | 30,662 | Jun 28 04:48 PM | | Durkin Brian L | VP, Controller | Mar 25 | Sale | 79.69 | 475 | 37,853 | 9,121 | Mar 25 04:34 PM | | Schumacher Laura J | Vice Chairman | Mar 14 | Sale | 80.00 | 25,000 | 2,000,000 | 139,838 | Mar 15 05:53 PM | | SALEKI-GERHARDT AZITA | EVP, Operations | Mar 05 | Sale | 79.03 | 15,797 | 1,248,480 | 93,312 | Mar 06 05:03 PM |
|
|
|
|
|
|
